417 related articles for article (PubMed ID: 19886884)
1. Hydrosoluble medicated nail lacquers: in vitro drug permeation and corresponding antimycotic activity.
Monti D; Saccomani L; Chetoni P; Burgalassi S; Senesi S; Ghelardi E; Mailland F
Br J Dermatol; 2010 Feb; 162(2):311-7. PubMed ID: 19886884
[TBL] [Abstract][Full Text] [Related]
2. Ciclopirox vs amorolfine: in vitro penetration into and permeation through human healthy nails of commercial nail lacquers.
Monti D; Tampucci S; Chetoni P; Burgalassi S; Mailland F
J Drugs Dermatol; 2014 Feb; 13(2):143-7. PubMed ID: 24509963
[TBL] [Abstract][Full Text] [Related]
3. Nail penetration and predicted mycological efficacy of an innovative hydrosoluble ciclopirox nail lacquer vs. a standard amorolfine lacquer in healthy subjects.
Monti D; Herranz U; Dal Bo L; Subissi A
J Eur Acad Dermatol Venereol; 2013 Feb; 27(2):e153-8. PubMed ID: 22449201
[TBL] [Abstract][Full Text] [Related]
4. In vitro transungual permeation of ciclopirox from a hydroxypropyl chitosan-based, water-soluble nail lacquer.
Monti D; Saccomani L; Chetoni P; Burgalassi S; Saettone MF; Mailland F
Drug Dev Ind Pharm; 2005 Jan; 31(1):11-7. PubMed ID: 15704853
[TBL] [Abstract][Full Text] [Related]
5. Antifungal activity, experimental infections and nail permeation of an innovative ciclopirox nail lacquer based on a water-soluble biopolymer.
Togni G; Mailland F
J Drugs Dermatol; 2010 May; 9(5):525-30. PubMed ID: 20480796
[TBL] [Abstract][Full Text] [Related]
6. Validation of bovine hoof slices as a model for infected human toenails: in vitro ciclopirox transungual permeation.
Monti D; Saccomani L; Chetoni P; Burgalassi S; Tampucci S; Mailland F
Br J Dermatol; 2011 Jul; 165(1):99-105. PubMed ID: 21410668
[TBL] [Abstract][Full Text] [Related]
7. In vitro antimycotic activity and nail permeation models of a piroctone olamine (octopirox) containing transungual water soluble technology.
Dubini F; Bellotti MG; Frangi A; Monti D; Saccomani L
Arzneimittelforschung; 2005; 55(8):478-83. PubMed ID: 16149717
[TBL] [Abstract][Full Text] [Related]
8. Development of ciclopirox nail lacquer with enhanced permeation and retention.
Thapa RK; Choi JY; Go TG; Kang MH; Han SD; Jun JH; Son MW; Yong CS; Kim JO
Arch Pharm Res; 2016 Jul; 39(7):953-9. PubMed ID: 27306785
[TBL] [Abstract][Full Text] [Related]
9. A randomized comparison of nail surface remanence of three nail lacquers, containing amorolfine 5%, ciclopirox 8% or tioconazole 28%, in healthy volunteers.
Sidou F; Soto P
Int J Tissue React; 2004; 26(1-2):17-24. PubMed ID: 15573688
[TBL] [Abstract][Full Text] [Related]
10. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis.
Bohn M; Kraemer KT
J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S57-69. PubMed ID: 11051135
[TBL] [Abstract][Full Text] [Related]
11. Optimized Ciclopirox-Based Eudragit RLPO Nail Lacquer: Effect of Endopeptidase Enzyme as Permeation Enhancer on Transungual Drug Delivery and Efficiency Against Onychomycosis.
Khattab A; Shalaby S
AAPS PharmSciTech; 2018 Apr; 19(3):1048-1060. PubMed ID: 29138987
[TBL] [Abstract][Full Text] [Related]
12. Loceryl nail lacquer--realization of a new galenical approach to onychomycosis therapy.
Pittrof F; Gerhards J; Erni W; Klecak G
Clin Exp Dermatol; 1992 Sep; 17 Suppl 1():26-8. PubMed ID: 1458660
[TBL] [Abstract][Full Text] [Related]
13. In vitro permeation and penetration of ciclopirox olamine from poloxamer 407-based formulations--comparison of isolated human stratum corneum, bovine hoof plates and keratin films.
Täuber A; Müller-Goymann CC
Int J Pharm; 2015 Jul; 489(1-2):73-82. PubMed ID: 25895717
[TBL] [Abstract][Full Text] [Related]
14. Ciclopirox Hydroxypropyl Chitosan (CPX-HPCH) Nail Lacquer and Breathable Cosmetic Nail Polish: In Vitro Evaluation of Drug Transungual Permeation Following the Combined Application.
Monti D; Tampucci S; Paganini V; Burgalassi S; Chetoni P; Galván J; Celandroni F; Ghelardi E
Life (Basel); 2022 May; 12(6):. PubMed ID: 35743832
[TBL] [Abstract][Full Text] [Related]
15. Ciclopirox delivery into the human nail plate using novel lipid diffusion enhancers.
Hafeez F; Hui X; Selner M; Rosenthal B; Maibach H
Drug Dev Ind Pharm; 2014 Jun; 40(6):838-44. PubMed ID: 23600655
[TBL] [Abstract][Full Text] [Related]
16. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis.
Gupta AK; Fleckman P; Baran R
J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S70-80. PubMed ID: 11051136
[TBL] [Abstract][Full Text] [Related]
17. Ciclopirox nail lacquer for the treatment of onychomycosis: an open non-comparative study.
Shemer A; Nathansohn N; Trau H; Amichai B; Grunwald MH
J Dermatol; 2010 Feb; 37(2):137-9. PubMed ID: 20175847
[TBL] [Abstract][Full Text] [Related]
18. An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis.
Baran R; Tosti A; Hartmane I; Altmeyer P; Hercogova J; Koudelkova V; Ruzicka T; Combemale P; Mikazans I
J Eur Acad Dermatol Venereol; 2009 Jul; 23(7):773-81. PubMed ID: 19453778
[TBL] [Abstract][Full Text] [Related]
19. Comparison of user-friendliness and treatment cost of Loceryl® vs. Ciclopoli®--a patient's perspective.
Schaller M; Braunsdorf C; Mailänder-Sanchez D; Jäckel A; Müller J; Borelli C
Mycoses; 2015 Oct; 58(10):632-6. PubMed ID: 26393437
[TBL] [Abstract][Full Text] [Related]
20. The dermatopharmacologic profile of ciclopirox 8% nail lacquer.
Bohn M; Kraemer K
J Am Podiatr Med Assoc; 2000; 90(10):491-4. PubMed ID: 11107709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
